OBJECTIVES The aim of this study was to determine the predictors of adverse events in pregnant women with cardiomyopathy (CDM) and CDM subtypes at the time of delivery.
. A growing concern is the presence of pre-existing and new onset cardiomyopathy (CDM) during pregnancy that may result in clinical decompensation with overt heart failure, arrhythmias, and even maternal death, particularly at the time of delivery (6) . Delivery of the fetus presents an additional hemodynamic insult for pregnant women with CDM and therefore a period of elevated risk. CDM in pregnancy, including peripartum CDM, has a low incidence, approximately 1 in 3,000 to 1 in 4,000 births (7, 8) . The incidence of other forms of CDM in pregnancy, including hypertrophic CDM and dilated CDM, is largely unknown, but these types are considered uncommon, thus making epidemiological studies on women with CDM challenging. Investigation into the patients' characteristics and outcomes in CDM has been mainly limited to small cohorts of patients (9) (10) (11) (12) , with only 1 recent study using hospital records pooled from 6 states limited to women with peripartum CDM (13) .
In this study, we sought to characterize the incidence of CDM in pregnant women in the (14) . The NIS provides annual information on approximately 8 million inpatient stays from about 1,000 hospitals and estimates a 20% stratified sample from a sampling frame that comprises 90% of U.S. acute care hospital admissions.
International Classification of th Revision (ICD-9) codes were used to ascertain hospitalizations for delivery, defined as any discharge record with a normal delivery or other indications for care in pregnancy, labor, and delivery-related diagnoses (ICD-9 codes 650 to 659 and V27.4 to V27.9) or delivery-related procedure (ICD-9 codes 72 to 75), as previously described (15). Our analysis was limited to delivery-associated hospitalizations to avoid including multiple hospitalizations for a given patient over the course of an individual pregnancy. Table 2 . Table 3) . Race was a significant predictor of MACE, with the highest risk among blacks compared with whites. Values are mean AE SD or n (%). *In the "other CDM" category, 92% (n ¼ 909) of these patients were classified as having dilated cardiomyopathy.
P r e d i c t o r s o f M A C E i n w o m e n w i t h c a r d i o m y op a t h y a n d p e r i p a r t u m c a r d i o m y o p a t h y .
CDM ¼ cardiomyopathy; HMO ¼ health maintenance organization; HTN ¼ hypertension.
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(OR: 2.16; 95% CI 1.49 to 3.14) ( CDM in a young cohort, to evaluate outcomes at the time of delivery. It has been previously used to investigate trends in hospitalization of pregnancy and heart disease, as well as trends in admission for heart failure or in myocardial infarction (16) (17) (18) (19) (20) . In anesthesia teams at the time of delivery. Overwhelmingly, the most common adverse outcome was heart failure, regardless of subtype of CDM, with more than one-third of the patients with peripartum CDM experiencing this outcome. Notably, heart failure was present in patients without CDM (Table 1) , presumably related to other cardiac conditions that are associated with heart failure in pregnancy (valvular disease, pulmonary hypertension, congenital heart disease). Recently, the ROPAC registry demonstrated that in a diverse group of patients, including those with congenital heart disease, CDM, and valvular heart disease, the most common adverse outcome was heart failure and was associated with higher adverse maternal and fetal outcome (26) .
Counseling women with known CDM of any subtype of these risks before pregnancy or during pregnancy is of critical importance. Moreover, reduction in heart failure frequency and severity should be a Other insurance 1.39 (0.89-2.16) *Factors (e.g., hospital region) are delineated by specific effects (e.g., Midwest, South, and West) as listed in the table, or otherwise, if not listed, the effect on the factor is yes vs. no. The multivariable logistic regression model for patients with CDM was performed in which all factors had a p value <0.1 in univariate models and their 2-way interaction terms were taken into account.
goal, particularly at the time of delivery and in the days to weeks that follow. Although the observed in-hospital mortality appears to be low in this cohort, and in others (9,13), a finding that is reassuring, it is possible that in these high-risk women, maternal death could occur after hospitalization for delivery. We demonstrated an increased incidence of hypertensive-related and/or pre-eclampsia/eclampsia disorders in our CDM cohort, particularly in the group with peripartum CDM. In addition, eclampsia status was found to be a significant predictor of MACE in our CDM cohort, as well as in the peripartum CDM cohort. Earlier evidence has suggested that preeclampsia/eclampsia was more common in women with peripartum CDM (8, 27, 28) , and it was a risk factor for the development of peripartum CDM (13).
Pre-eclampsia/eclampsia may be a contributor to impairment in cardiac function. Consistent with this concept, several studies have shown that women with pre-eclampsia have evidence of diastolic dysfunction as well as impaired myocardial strain MACE ¼ major adverse cardiac events; other abbreviations as in Table 3 . There is increasing evidence for the relationship of race with pregnancy complications in women with peripartum CDM (13, 33) . Peripartum CDM has been traditionally characterized by prominent rates among black women (33, 34) , but it is recognized that this depends on the population studied and the incidence varies in women of different racial backgrounds (11, 33, 34) . We noted in our analyses that white women overall represented the highest number of cases per CDM cohort. However, the white race also represented the largest overall sample size among the races in our study. When assessing for frequency of cases classified by race, we noted that black women had more than a 2-fold higher rate of peripartum CDM and all other CDM types (0.0005 and 0.0005, respectively) compared with white women (0.0002 and 0.0002, respectively). Elkayam et al. (12) similarly described this finding in their study, in which white women were the most represented race in their sample and therefore also had the highest weight on the peripartum CDM frequencies across races.
Cesarean delivery was most common in the CDM cohort overall, and most common in the peripartum CDM cohort, and it was a predictor of adverse events.
This likely reflects the degree of clinical acuity and the severity of illness. However, an interaction related to anesthesia in the maternal outcomes cannot be excluded. Hospital admissions for delivery in women with and without CDM were identified through ICD-9 codes and therefore were unable to be independently adjudicated. Errors in ICD-9 coding and documentation are possible, although the error rate has been found to be low in this database (16) . ICD-9-Clinical Modification (ICD-9-CM) coding has demonstrated a high specificity and positive predictive value for related diseases such as heart failure and hypertensive disorders (18, (35) (36) (37) .
Although diagnostic accuracy remains a concern, it is reassuring that our data are similar to others with regard to incidence, demographic data, and known risk factors.
CONCLUSIONS
With a large all-payer population of U.S. pregnant women at delivery, we observed that MACE occurred in more than 40% of the CDM cohort at the time of delivery compared with the less than 1% in the No CDM cohort, with a strikingly low overall mortality rate in the CDM group. MACE in the CDM cohort was mainly driven by heart failure and, to a lesser extent, arrhythmias. MACE was also noted to be prevalent in all 3 CDM subgroups, with the highest overall incidence in the peripartum CDM subgroup. 
